Stock Track | HBM Holdings-B Soars 6.59% as Subsidiary Inks License Deal with Pfizer

Stock Track

Nov 20, 2025

HBM Holdings-B (02142) saw its stock price soar 6.59% during the intraday trading session, reaching HK$14.68. The surge comes on the heels of a significant announcement made by the company regarding its wholly-owned subsidiary, Nona Biotechnology (Suzhou) Co., Ltd.

On November 19, HBM Holdings-B revealed that Nona Biotechnology had entered into a non-exclusive license agreement with pharmaceutical giant Pfizer. This partnership aims to advance preclinical antibody discovery for multiple potential disease indications. Under the terms of the agreement, Pfizer will gain global access to Nona Biotechnology's proprietary HCAb platform, which is used for developing fully human heavy-chain-only antibodies.

The deal structure includes an upfront payment to Nona Biotechnology, with the potential for additional regulatory, clinical, and commercial milestone payments. Furthermore, the agreement opens up opportunities for collaborative efforts between Nona Biotechnology and Pfizer, leveraging the former's HCAb platform, advanced B-cell screening technology, and integrated services for antibody discovery, development, and engineering. This strategic partnership has evidently boosted investor confidence, contributing to the significant uptick in HBM Holdings-B's stock price.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1134266831"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1134266831\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1134266831?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-20 09:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1134266831","market":"sg","top_or_hot":-1,"title":"Stock Track | HBM Holdings-B Soars 6.59% as Subsidiary Inks License Deal with Pfizer","media":"Stock Track","content":"<p>HBM Holdings-B (02142) saw its stock price soar 6.59% during the intraday trading session, reaching HK$14.68. The surge comes on the heels of a significant announcement made by the company regarding its wholly-owned subsidiary, Nona Biotechnology (Suzhou) Co., Ltd.</p>\n\n<p>On November 19, HBM Holdings-B revealed that Nona Biotechnology had entered into a non-exclusive license agreement with pharmaceutical giant Pfizer. This partnership aims to advance preclinical antibody discovery for multiple potential disease indications. Under the terms of the agreement, Pfizer will gain global access to Nona Biotechnology's proprietary HCAb platform, which is used for developing fully human heavy-chain-only antibodies.</p>\n\n<p>The deal structure includes an upfront payment to Nona Biotechnology, with the potential for additional regulatory, clinical, and commercial milestone payments. Furthermore, the agreement opens up opportunities for collaborative efforts between Nona Biotechnology and Pfizer, leveraging the former's HCAb platform, advanced B-cell screening technology, and integrated services for antibody discovery, development, and engineering. This strategic partnership has evidently boosted investor confidence, contributing to the significant uptick in HBM Holdings-B's stock price.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | HBM Holdings-B Soars 6.59% as Subsidiary Inks License Deal with Pfizer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | HBM Holdings-B Soars 6.59% as Subsidiary Inks License Deal with Pfizer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-20 09:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HBM Holdings-B (02142) saw its stock price soar 6.59% during the intraday trading session, reaching HK$14.68. The surge comes on the heels of a significant announcement made by the company regarding its wholly-owned subsidiary, Nona Biotechnology (Suzhou) Co., Ltd.</p>\n\n<p>On November 19, HBM Holdings-B revealed that Nona Biotechnology had entered into a non-exclusive license agreement with pharmaceutical giant Pfizer. This partnership aims to advance preclinical antibody discovery for multiple potential disease indications. Under the terms of the agreement, Pfizer will gain global access to Nona Biotechnology's proprietary HCAb platform, which is used for developing fully human heavy-chain-only antibodies.</p>\n\n<p>The deal structure includes an upfront payment to Nona Biotechnology, with the potential for additional regulatory, clinical, and commercial milestone payments. Furthermore, the agreement opens up opportunities for collaborative efforts between Nona Biotechnology and Pfizer, leveraging the former's HCAb platform, advanced B-cell screening technology, and integrated services for antibody discovery, development, and engineering. This strategic partnership has evidently boosted investor confidence, contributing to the significant uptick in HBM Holdings-B's stock price.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02142","symbol_name":"和铂医药-B","start_time":0,"source_url":"","article_id":"1134266831","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1134266831","pubTimestamp":1763603557,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"HBM Holdings-B (02142) saw its stock price soar 6.59% during the intraday trading session, reaching HK$14.68. The surge comes on the heels of a significant announcement made by the company regarding...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02142":"和铂医药-B"},"translate_title":"个股追踪|子公司与辉瑞签署许可协议HBM Holdings-B飙升6.59%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02142":1},"content_text":"HBM Holdings-B (02142) saw its stock price soar 6.59% during the intraday trading session, reaching HK$14.68. The surge comes on the heels of a significant announcement made by the company regarding its wholly-owned subsidiary, Nona Biotechnology (Suzhou) Co., Ltd.\nOn November 19, HBM Holdings-B revealed that Nona Biotechnology had entered into a non-exclusive license agreement with pharmaceutical giant Pfizer. This partnership aims to advance preclinical antibody discovery for multiple potential disease indications. Under the terms of the agreement, Pfizer will gain global access to Nona Biotechnology's proprietary HCAb platform, which is used for developing fully human heavy-chain-only antibodies.\nThe deal structure includes an upfront payment to Nona Biotechnology, with the potential for additional regulatory, clinical, and commercial milestone payments. Furthermore, the agreement opens up opportunities for collaborative efforts between Nona Biotechnology and Pfizer, leveraging the former's HCAb platform, advanced B-cell screening technology, and integrated services for antibody discovery, development, and engineering. This strategic partnership has evidently boosted investor confidence, contributing to the significant uptick in HBM Holdings-B's stock price.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}